Lanthionine Ketimine Ethyl Ester Accelerates Remyelination in a Mouse Model of Multiple Sclerosis

Area of Science:

• Neuroscience
• Neuroimmunology
• Regenerative Medicine

Background:

• Multiple Sclerosis (MS) treatments lack remyelination and axon protection.
• Lanthionine ketenamine ethyl ester (LKE) previously showed promise in MS models.
• Oligodendrocyte progenitor cells (OPCs) are crucial for myelin repair.

Purpose of the Study:

• To investigate LKE's efficacy in promoting remyelination in the cuprizone (CPZ) demyelination model of MS.
• To assess LKE's impact on oligodendrocyte maturation and myelin repair markers.

Main Methods:

• Cuprizone (CPZ) diet-induced demyelination model in mice.
• Treatment with LKE or vehicle.
• Analysis using immunohistochemistry (IHC), electron microscopy, and mRNA expression.

Main Results:

• LKE significantly increased myelinated axon number and myelin thickness in the corpus callosum (CC).
• LKE elevated myelin basic protein (MBP) and proteolipid protein (PLP) expression.
• LKE increased mature oligodendrocyte numbers but not OPC proliferation, suggesting enhanced differentiation and survival.

Conclusions:

• LKE demonstrates significant remyelination potential in a CPZ-induced demyelination model.
• LKE's mechanism involves promoting oligodendrocyte maturation and survival, not proliferation.
• LKE represents a promising therapeutic candidate for remyelination in MS and other demyelinating disorders.